NCT01825759

Brief Summary

The Impact of Compound danshen dropping pill for coronary heart disease (CHD) heart and artery structure and function in patients with hypertension

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
200

participants targeted

Target at P75+ for phase_4

Timeline
Completed

Started Jan 2013

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2013

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

March 26, 2013

Completed
13 days until next milestone

First Posted

Study publicly available on registry

April 8, 2013

Completed
1.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2014

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2014

Completed
Last Updated

April 8, 2013

Status Verified

March 1, 2013

Enrollment Period

1.9 years

First QC Date

March 26, 2013

Last Update Submit

April 5, 2013

Conditions

Coronary Heart DiseaseEssential Hypertension

Outcome Measures

Primary Outcomes (1)

  • Pulse wave velocity

    one year

Secondary Outcomes (1)

  • ankle-brachial index

    one year

Other Outcomes (1)

  • intima-media thickness,methyl-di-aide-hyde

    one year

Study Arms (1)

danshen dripping pill

EXPERIMENTAL

danshen dripping pill 27mg ten pills by mouth every 8 hours for one year

Drug: danshen dripping pill

Interventions

danshen dripping pillDRUG
Also known as: compound danshen dripping pill
danshen dripping pill

Eligibility Criteria

Age35 Years - 75 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

West China Hospital

Chengdu, Sichuan, China

RECRUITING

Related Links

MeSH Terms

Conditions

Coronary DiseaseEssential Hypertension

Interventions

danshen dripping pill

Condition Hierarchy (Ancestors)

Myocardial IschemiaHeart DiseasesCardiovascular DiseasesVascular DiseasesHypertension

Study Officials

  • chen xi ping, master

    organizer

    STUDY DIRECTOR

Central Study Contacts

chen xi ping, master

CONTACT

028-85423352panpei74@163.com

Study Design

Study Type
interventional
Phase
phase 4
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Compound danshen dropping pill for coronary heart disease with hypertension patient heart and artery structure and function

Study Record Dates

First Submitted

March 26, 2013

First Posted

April 8, 2013

Study Start

January 1, 2013

Primary Completion

December 1, 2014

Study Completion

December 1, 2014

Last Updated

April 8, 2013

Record last verified: 2013-03

Locations

CN(1)